2009   Dec, 22 Lupin Announces Litigation Settlement with Forest for Memantine Tablets   Oct, 26 Lupin Q2 Net Profit up 39%   Oct, 05 Lupin licenses us rights for proprietary bioadhesive technology for rifaximin to salix pharmaceuticals   Sept, 29 Lupin Expands Branded Play Announces Acquisition of US Rights to ANTARA   July, 29 Lupin Net Profit up by 25 % in Q1, FY 2009-10 Outpacing and Outperforming Markets globally   June, 30 Lupin Expands Branded Play Announces Acquisition of Worldwide Rights for its first NDA - AllerNaze™   May, 13 Lupin Q4 & FY 2008-09 Results - Consistent Performance & Solid Growth   May, 11 Lupin Announces Litigation Settlement with Wyeth for Venlafaxine Extended Release Capsules   April, 09 Alliance to commercialize generic equivalent of FOSRENOL® Tablets   March, 26 Lupin acquires majority stake in Multicare Pharmaceuticals Philippines, Inc.   March, 09 Lupin ties up with leading Institutes for PhD Program   Jan, 29 Lupin Q3 FY 08-09 – Strong Growth & Consistent Performance   Jan, 16 Lupin receives USFDA approval for Levetiracetam Tablets